Carboxylic Acid Ester Patents (Class 514/785)
-
Publication number: 20140371333Abstract: An organogelling agent for forming reverse worm-like micelles having high safety to living bodies and the environment, favorable feel of use, and a high gelating ability and a thickened gel composition comprising the organogelling agent are provided. Lecithin and ascorbic acid or an ascorbic acid derivative act as an organogelling agent to form reverse worm-like micelles of a variety of oils. A thickened gel composition having a reverse worm-like micelle structure can be prepared with a ternary system of lecithin, ascorbic acid or an ascorbic acid derivative, and a variety of oils.Type: ApplicationFiled: November 30, 2012Publication date: December 18, 2014Inventors: Kaname Hashizaki, Yoshihiro Saito, Hiroyuki Taguchi
-
Publication number: 20140370081Abstract: The invention relates to enantiomerically pure DOTAP chloride and stable crystal modifications of (2R,S)-, (25)- and (2R)-DOTAP chloride, to a process for the preparation of these modifications, and to the use thereof as constituent for the preparation of medicaments.Type: ApplicationFiled: September 2, 2014Publication date: December 18, 2014Applicant: Merck Patent GmbHInventors: Michael Platscher, Alfred Hedinger
-
Publication number: 20140357600Abstract: Described herein are compositions (e.g., a pharmaceutical composition) and methods for controlling the delivery of a therapeutic agent, and their use in the treatment and/or prevention of diseases and disorders.Type: ApplicationFiled: June 6, 2014Publication date: December 4, 2014Applicant: CHEMIC LABORATORIES INC.Inventors: Joseph P. St. Laurent, Scott A. Goodrich, Gerald S. Jones, Jr.
-
Publication number: 20140357731Abstract: A method for formulating a cationic and non-ionic oil in water emulsion, preferably in a cream form, containing growth factors, preferably platelet derived growth factors, specific matrikine peptides, botanicals, emollients, nano-molecules, antioxidants, antiseptics, neuro-peptides, anti-dermatophytics, polysaccharides, sensorial peptides, osmotically driven moisturizers, and siloxane barriers. For application to the feet and other affected parts of the body for the relief of diabetic skin and tissue trauma.Type: ApplicationFiled: June 3, 2014Publication date: December 4, 2014Inventor: ALVIN DAVID NEEDLEMAN
-
Patent number: 8900603Abstract: The invention relates to oligofluorinated coatings and their use in drag delivery The oligofluorinated coatings are compositions comprising formula (XVII). These coatings are used in a method of delivering a biologically active agent to a tissue surface in a mammalian tissue This method occurs by contacting the surface with the coating including an oligofluorinated oligomer and a biologically active agent wherein the coating resides on the tissue surface and release the biologically active agent to the tissue surface.Type: GrantFiled: December 20, 2010Date of Patent: December 2, 2014Assignee: Interface Biologics, Inc.Inventors: Roseita Esfand, J. Paul Santerre, Sylvia Tjahyadi, Bernadette Ilagan
-
Patent number: 8901347Abstract: Disclosed are novel bioabsorbable and biodegradable monomer compounds, bioabsorbable and biodegradable polymers therefrom, and methods of making such monomers and polymers, which are useful in pharmaceutical delivery systems, tissue engineering applications, tissue adhesives products, implantable medical devices, foams and reticulated foams for wound healing and drug delivery, bone hemostats and bone void fillers, adhesion prevention barriers, meshes, filters, stents, medical device coatings, pharmaceutical drug formulations, consumer product and cosmetic and pharmaceutical packaging, apparel, infusion devices, blood collection tubes and devices, other medical tubes, skin care products, and transdermal drug delivery materials.Type: GrantFiled: October 18, 2011Date of Patent: December 2, 2014Assignee: Bezwada Biomedical, LLCInventor: Rao S. Bezwada
-
Publication number: 20140348767Abstract: Provided is a compound capable of gelling various aqueous compositions containing salt, acid and the like. An amphoteric ion-type basic amino acid derivative represented by the formula (1A): wherein each substituent is as defined in DESCRIPTION, or a salt thereof.Type: ApplicationFiled: August 6, 2014Publication date: November 27, 2014Applicant: AJINOMOTO CO., INC.Inventors: Kenji HANABUSA, Masahiro SUZUKI, Takanori SUGIMOTO
-
Publication number: 20140343171Abstract: Compositions comprising isosorbide monoesters and hydroxypyridones What are described are compositions comprising a) one or more compounds of the formula (I) in which R is a straight-chain or branched saturated alkyl group having 5 to 11 carbon atoms or a straight-chain or branched mono- or polyunsaturated alkenyl group having 5 to 11 carbon atoms, and b) one or more substances selected from the group consisting of hydroxypyridones and their salts. The compositions are distinguished in particular by an advantageous antimicrobial activity.Type: ApplicationFiled: July 31, 2012Publication date: November 20, 2014Applicant: CLARIANT INTERNATIONAL LTD.Inventors: Maurice Frederic Pilz, Peter Klug, Franz-Xaver Scherl, Joerg Grohmann
-
Patent number: 8889189Abstract: There are described solid compositions or examining drug solubility comprising bile salts and phospholipids, optionally containing buffer components suitable for preparation of intestinal media that simulate the composition of the intestinal fluids in fasted and fed states.Type: GrantFiled: October 16, 2012Date of Patent: November 18, 2014Assignee: Phares Pharmaceutical Research, N.V.Inventors: Steve Leigh, Mathew Louis Steven Leigh, Peter Van Hoogevest, Daniel Streich, Jacques Quinton
-
Publication number: 20140335166Abstract: A method for preparing a phospholipid delivery system encapsulating one or more bio-affecting compounds, includes the steps of solubilizing a heterogeneous phospholipid mixture into an organic solvent to form a concentrated formulation of phospholipids, in which the phospholipids include a charged phospholipid species and mixing the concentrated formulation with an aqueous solution having at least one bio-affecting compound. A method of using a phospholipid delivery system encapsulating at least one bio-affecting compound for the administration to an individual in need thereof is also disclosed.Type: ApplicationFiled: May 8, 2013Publication date: November 13, 2014Inventor: Michael W. Fountain
-
Publication number: 20140336279Abstract: The disclosure relates to the use of an oil emulsion for acaricidal, insecticidal, and antifungal treatment of the stems and leaves of a plant during the growth thereof in confined, intensive-cultivation spaces, the emulsion including water and a paraffin oil obtained from petroleum and having a boiling point of 200° C. to 450° C., a viscosity of no more than 20 mm2/s at 40° C., and an unsulfonated residue content of no less than 99% according to the ASTM D483 standard, and further including at least 20 wt % of mono- or polycyclic naphthenes, the paraffinic oil being introduced as a stable emulsifiable concentrate including water.Type: ApplicationFiled: December 21, 2012Publication date: November 13, 2014Applicant: TOTAL MARKETING SERVICESInventor: Eric Bureau
-
Patent number: 8883221Abstract: Micronutrient combination product, wherein the micronutrient combination product comprises zeaxanthin, lutein, zinc and copper.Type: GrantFiled: December 17, 2004Date of Patent: November 11, 2014Assignee: Bausch & Lomb IncorporatedInventors: Guenter Bellmann, Gudrun Claus-Herz
-
Patent number: 8883185Abstract: The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.Type: GrantFiled: May 24, 2011Date of Patent: November 11, 2014Assignee: Covidien LPInventors: Steven Bennett, Nathaniel Mast, Kevin Lavigne, Walter Skalla, Saumya Banerjee, Timothy Sargeant, Joshua Stopek
-
Patent number: 8883767Abstract: A low ether gel composition for application to skin comprising a keratolytic agent, in particular salicylic acid, and comprising a nitrocellulose and one or more volatile ingredients, which forms a film on contact with skin adequate to form a protective barrier for the keratolytic agent for a period of time necessary to provide treatment to the skin; methods of treating using such compositions, and dispensers containing such compositions.Type: GrantFiled: October 4, 2010Date of Patent: November 11, 2014Assignee: MSD Consumer Care, Inc.Inventors: Gerald R. Dever, Eric Chen-nan Su, William Scott Rogersr, Robert C. Johnson
-
Publication number: 20140329793Abstract: The invention features pharmaceutical compositions including (i) a drug, and (ii) a PEG fatty acid ester or PPG fatty acid ester in an amount sufficient to increase the oral bioavailability of the drug.Type: ApplicationFiled: October 19, 2012Publication date: November 6, 2014Applicant: SEACHAID PHARMACEUTICALS, INC.Inventors: Balasingam Radhakrishnan, Anuradha Vaidya, Navdeep Balkrishna Malkar, Karen Polowy, Kenneth Duke James, JR.
-
Publication number: 20140328938Abstract: Biodegradable pharmaceutical compositions comprising 1,3-propanediol and its esters are provided. The 1,3-propanediol and its esters in the pharmaceutical composition are biologically derived, and as such, the pharmaceutical compositions exhibit a low anthropogenic CO2 emission profile.Type: ApplicationFiled: July 14, 2014Publication date: November 6, 2014Applicant: DuPont Tate & Lyle Bio Products Company, LLCInventors: Robert Miller, Joseph Desalvo, Gyorgyi Fenyvesi, Melissa Joerger, Raja Hari Poladi, Ann Wehner
-
Patent number: 8877234Abstract: The invention relates to clear, liquid preservatives, which contain a) one or several 1-hydroxy-4-methyl-6-alkyl-2(1H)-pyridones and/or one or several salts thereof, wherein alkyl represents a linear, branched or cyclic alkyl group having 1-12 carbon atoms, and b) one or several alcohols containing one or several aromatic groups.Type: GrantFiled: January 25, 2006Date of Patent: November 4, 2014Assignee: Clariant Finance (BVI) LimitedInventors: Waltraud Simsch, {dot over (P)}eter Klug, Sonja Klein
-
Publication number: 20140323592Abstract: The use of one or more compounds of the formula (I) in which R is a straight-chain or branched saturated alkyl group having 5 to 11 carbon atoms or a straight-chain or branched mono- or polyunsaturated alkenyl group having 5 to 11 carbon atoms as thickeners is described. The use is preferably in cosmetic, dermatological or pharmaceutical compositions, in crop protection formulations, in washing or cleaning compositions or in paints or coatings.Type: ApplicationFiled: July 31, 2012Publication date: October 30, 2014Applicant: CLARIANT INTERNATIONAL LTD.Inventors: Maurice Frederic Pilz, Peter Klug, Franz-Xaver Scherl
-
Publication number: 20140314852Abstract: The invention relates to systems comprising homogenous nanoparticles having an average size of less than 1 micrometer and containing at least a sorbitan ester, a macrogol ester, a macrogol ether or a derivative of same and, optionally, at least one component derived from oxyethylene and/or at least one component having an electric charge (positive or negative). According to the invention, the components are incorporated in a single step consisting in mixing two solutions. The invention also relates to the use of said systems as medicines or medical devices, in tissue engineering or regenerative medicine, for cosmetic, hygienic or nutritional uses, and in surface coatings. The invention further relates to methods for preparing same.Type: ApplicationFiled: November 8, 2012Publication date: October 23, 2014Inventors: Alejandro Sanchez Barreiro, Begoña Seijo Rey, Giovanni Konat Zorzi, Edison Luis Santana Carvalho, Andrea Pensado Lopez
-
Publication number: 20140309277Abstract: Disclosed are formulation and optimization protocols for delivery of therapeutically effective amounts of biologically active agents to liver, tumors, and/or other cells or tissues. Also provided are compositions and uses for cationic lipid compounds of formula (I). The invention also relates to compositions and uses for stealth lipids of formula (XI). Also provided are processes for making such compounds, compositions, and formulations, plus methods and uses of such compounds, compositions, and formulations to deliver biologically active agents to cells and/or tissues.Type: ApplicationFiled: March 4, 2014Publication date: October 16, 2014Applicant: NOVARTIS AGInventors: Jeremy BARYZA, Keith BOWMAN, Andrew GEALL, Tanzina LABONTE, Cameron LEE, Chandra VARGEESE, Laura WEST, Junping ZHAO
-
Publication number: 20140308304Abstract: The present invention relates to novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides, to facilitate the cellular uptake and endosomal escape, and to knockdown target mRNA both in vitro and in vivo. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.Type: ApplicationFiled: December 7, 2012Publication date: October 16, 2014Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Martin Maier
-
Publication number: 20140308360Abstract: The invention provides multivalent surface-crosslinked micelle (SCM) particles, crosslinked reverse micelle (CRM) particles, and methods of making and using them. The SCM particles can be used, for example, to inhibit a virus or bacteria from binding to a host cell. The inhibition can be used in therapy for the flu, cancer, or AIDS. The CRM particles can be used, for example, to prepare metal nanoparticles or metal alloy nanoparticles, or they can be used in catalytic reactions.Type: ApplicationFiled: June 26, 2014Publication date: October 16, 2014Inventor: Yan Zhao
-
Patent number: 8852648Abstract: A composition and method adapted for delivery of hydrophilic, biologically-active agents are disclosed. The composition can include a reverse microemulsion formed from at least one hydrophilic, biologically-active agent solubilized by a hydrophobic reverse emulsion surfactant in a non-stinging, volatile, hydrophobic solvent. The non-stinging, volatile, hydrophobic solvent is selected from the group consisting of volatile linear and cyclic siloxanes, volatile linear, branched, and cyclic alkanes, volatile fluorocarbons and chlorofluorocarbons, liquid carbon dioxide under pressure, and combinations thereof. The reverse microemulsion can be an optically clear solution.Type: GrantFiled: October 21, 2013Date of Patent: October 7, 2014Assignee: Rochal Industries, LLPInventors: Joseph Charles Salamone, Xiaoyu Chen, Ann Beal Salamone, Katelyn Elizabeth Reilly
-
Patent number: 8853283Abstract: The invention relates to enantiomerically pure DOTAP chloride and stable crystal modifications of (2R,S)-, (2S)- and (2R)-DOTAP chloride, to a process for the preparation of these modifications, and to the use thereof as constituent for the preparation of medicaments.Type: GrantFiled: November 7, 2005Date of Patent: October 7, 2014Assignee: Merck Patent GmbHInventors: Michael Platscher, Alfred Hedinger
-
Publication number: 20140294934Abstract: Here described are compounds of formula I: wherein R1 and R2 is independently selected from a group consisting of C10 to C18 alkyl, C12 to C18 alkenyl, and oleyl group; wherein R3 and R4 are independently selected from a group consisting of C1 to C6 alkyl, and C2 to C6 alkanol; wherein X is selected from a group consisting of —CH2—, —S—, and —O— or absent; wherein Y is selected from —(CH2)n, —S(CH2)n, —O(CH2)n—, thiophene, —SO2(CH2)n—, and ester, wherein n=1-4; wherein a=1-4; wherein b=1-4; wherein c=1-4; and wherein Z is a counterion; as well as compositions and pharmaceutical formulations including compounds of formula I which are useful for the delivery of therapeutic agents; and methods of using these compositions and formulations.Type: ApplicationFiled: April 18, 2014Publication date: October 2, 2014Applicant: Nitto Denko CorporationInventors: Yoshiro Niitsu, Victor Knopov, Joseph E. Payne, Zheng Hou, John A. Gaudette, Violetta Akopian, Richard P. Witte, Mohammad Ahmadian, Loren A. Perelman, Yasunobu Tanaka, Priya Karmali, Sridhar C. Nagarajan
-
Publication number: 20140296354Abstract: Described herein are the one-pot synthesis and characterization of a library of low molecular weight peptoid compounds that are able to form gels at room temperature. The compounds are synthesized from biologically-based starting materials, are biocompatible, and are resistant to degradation by proteases and peptidases.Type: ApplicationFiled: April 1, 2014Publication date: October 2, 2014Applicant: OLD DOMINION UNIVERSITY RESEARCH FOUNDATIONInventors: Guijun WANG, Hari P. R. MANGUNURU
-
Publication number: 20140294744Abstract: Disclosed herein is a dispersion comprising a liquid or semi-solid continuous phase, a dispersed solid phase comprising a plurality of organic, inorganic or inorganic-organic particles, and an alkyl ketal ester having the structure wherein a is 0 or an integer of 1 to 12, specifically 1 to 6, more specifically 1 to 4; b is 0 or 1; R2 is a divalent C1-8 group optionally substituted with up to 5 hydroxyl groups; and R1 is C1-6 alkyl, and wherein at least a portion of the alkyl ketal ester is present in the continuous phase, on a surface of at least some of the dispersed particles, or a combination thereof.Type: ApplicationFiled: March 31, 2014Publication date: October 2, 2014Applicant: SEGETIS, INC.Inventors: Lee Richard RIETH, Dorie J. YONTZ, Nicholas MORANTE
-
Publication number: 20140288146Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: ApplicationFiled: April 25, 2013Publication date: September 25, 2014Applicant: Protiva Biotherapeutics, Inc.Inventors: James Heyes, Mark Wood, Alan Martin
-
Patent number: 8841382Abstract: The present invention provides an amphiphile of the formula (I) as described hereinafter. The invention further relates to a process for preparing the amphiphile and to a composition comprising the amphiphile and a sparingly water-soluble active ingredient. It further relates to a process for producing the composition by contacting the amphiphile and the active ingredient, and to the use of the amphiphile for solubilizing a sparingly water-soluble active ingredient in aqueous solutions. The invention also relates to the use of the amphiphile in an agrochemical formulation comprising the amphiphile and a pesticide for controlling phytopathogenic fungi and/or unwanted vegetation and/or unwanted insect or mite infestation and/or for regulating the growth of plants, and finally to plant propagation material comprising the amphiphile.Type: GrantFiled: August 31, 2011Date of Patent: September 23, 2014Assignee: BASF SEInventors: Anna Cristadoro, Holger Türk, Michael Ishaque, Rabie Al-Hellani
-
Publication number: 20140271956Abstract: The present invention relates to a lamellar structure which stabilizes oil and to a cleansing composition comprising the lamellar structure. More particularly, the present invention relates to a lamellar structure, which stabilizes oil to be used in a cleansing composition so that high-content oil is converted to a lamellar phase and contained in a composition. The present invention also relates to a cleansing composition which comprises the lamellar structure which enables the composition to contain high-content oil in a stable manner and to thus provide superior moisturizing ability.Type: ApplicationFiled: October 8, 2012Publication date: September 18, 2014Inventors: Chang Jo Jung, Dae Kyeong Kim, John Hwan Lee, Wang Gi Kim
-
Publication number: 20140271528Abstract: Provided herein are pre-formulations forming a biocompatible hydrogel polymer comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the biocompatible hydrogel polymer covers a wound in a mammal and adheres to the surrounding skin tissue. In other embodiments, the hydrogel polymer is delivered into a joint space to treat joint disease or navicular disease.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: Medicus Biosciences LLCInventors: Syed H. ASKARI, Yeon S. CHOI, Paul YuJen WAN
-
Publication number: 20140275263Abstract: Provided are pharmaceutical carriers suitable based on oil-in-water microemulsions and methods of making same. Also provided are pharmaceutical compositions comprising a carrier of the invention and a lipophilic active pharmaceutical ingredient (API), as well as methods for making same. The pharmaceutical compositions are particularly suitable for use in formulating lipophilic APIs for topical administration to the eye. Specifically included are pharmaceutical compositions comprising fenofibrate or fenofibric acid as API. Also provided is a method of treating a disease of the posterior segment of the eye. Also provided is a pharmaceutical composition comprising a compound represented by formulated for topical administration to the eye.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: EyeCRO, LLCInventors: Ronald A. Wassel, Fadee G. Mondalek, Rafal A. Farjo, Alexander B. Quiambao, Didier J. Nuño
-
Publication number: 20140271596Abstract: The present invention relates to an emulsified hydrogel composition and to a production method therefor, wherein, by incorporating between 20 and 30 percent by weight of a gelling solution and an emulsion obtained by mixing between 45 and 60 percent by weight of an aqueous component and between 15 and 30 percent by weight of an oil component, it is possible to simultaneously provide the skin with an aqueous fraction and an oil fraction, and it is possible to enhance functionality due to the inclusion of a high content of a dermatologically active component dissolved in the oil component.Type: ApplicationFiled: September 12, 2012Publication date: September 18, 2014Applicant: GENIC CO., LTD.Inventors: Sung Jang Kim, Hyong-ii Park, Jae Han Cho, Eun Kyoung Choi, Jae hoon Kwak, Jae Min Lim, Hyun Jun Lim, Jai Hyun Kim, Min Seok Kim, Jin A. Yang, Hyun Oh Yoo, Jong Chul Kim
-
Patent number: 8835511Abstract: Absorbent articles provided with an odor control system. The odor control system includes at least two classes of odor control materials, wherein one class acts on malodors or a malodorous substance in the absorbent article and a second class acts on nose receptors. The classes of odor control materials may be selected to provide a synergistic effect in terms of malodor reduction.Type: GrantFiled: April 4, 2007Date of Patent: September 16, 2014Assignee: The Procter & Gamble CompanyInventors: Giovanni Carlucci, Antonella Pesce, Mariangela Caputi, Giancarlo Sierri, Alessandro Gagliardini
-
Publication number: 20140255320Abstract: The present invention relates to a composition for topical application comprising at least a benzotriazol derivative and vitamin E or a derivative thereof. Furthermore, the invention relates to compositions that prevent staining of clothes.Type: ApplicationFiled: June 6, 2012Publication date: September 11, 2014Applicant: DSM IP ASSETS B.V.Inventors: Christine Mendrok-Edinger, Horst Westenfelder
-
Patent number: 8828960Abstract: The invention relates to pharmaceutical compositions that provide sustained-release of a pharmaceutically active compound and to methods of treating or preventing a condition in an animal by administering the pharmaceutical compositions to the animal. When the pharmaceutical compositions are administered to an animal by injection, they form a drug depot that releases the pharmaceutically active compound over time. The pharmaceutical compositions can also be administered orally.Type: GrantFiled: July 11, 2008Date of Patent: September 9, 2014Assignee: IDEXX Laboratories, Inc.Inventors: Yerramilli V.S.N. Murthy, Michael Atkinson
-
Patent number: 8815944Abstract: The present invention relates to an injectable pharmaceutical composition with gelling properties containing: -an active principle; a hydrophobic and bio-compatible organic liquid; and an organogelling substance, the molecules of which have the capacity to bind together via bonds of low energy, wherein the organogelling substance is chosen among L-tyrosine derivatives responding to the following formula (I) wherein: R1 is an alkyl group containing 1 to 3 carbon atoms, linear or branched; and R2 is a hydrophobic group chosen among aliphatic saturated or unsaturated fatty chains or aryl or arylalkyl groups. Its use as a vector for the release of active principles, as well as its process of preparation.Type: GrantFiled: January 30, 2009Date of Patent: August 26, 2014Assignees: Ethypharm, Universite de MontrealInventors: Jean-Chrisophe Leroux, Guillaume Bastiat
-
Publication number: 20140234428Abstract: The invention, a transdermal delivery method, relates to penetration-enhancing pharmaceutical compositions comprising a novel, stable mixture of cetylated esters, cetyl or stearyl alcohols, polar solvents and surfactants, which, under appropriate conditions, combine into amphiphilic nanoparticles within a stabilized liquid dispersion for use in delivery of medicinal agents through the skin. The term cetosomes is used to describe these particles in order to differentiate them from other nanoparticles, such as niosomes, cerasomes, polymeric micelles, dendrimers, liposomes, lipoids, solid lipid nanoparticles and other particles. The self-assembling cetosomes, with both ionic and nonionic points of attraction, incorporate and concentrate a variety of different bioactive agents of interest and demonstrate stable properties with similarities to colloidal molecular structures. The compositions enhance topical transdermal fluxes of bioactives without permanently disrupting natural skin barrier function.Type: ApplicationFiled: February 15, 2013Publication date: August 21, 2014Applicant: Cymbiotics, Inc.Inventors: Raj R. Barathur, Jack Bain Bookout
-
Publication number: 20140228309Abstract: Stable formulations for the oral administration of therapeutic agents, methods for administering therapeutic agents using the formulations, and methods for treating conditions and diseases using the formulations.Type: ApplicationFiled: January 31, 2014Publication date: August 14, 2014Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventors: Kishor M. Wasan, Ellen K. Wasan
-
Patent number: 8802095Abstract: An injectable, nonaqueous suspension including at least one therapeutic agent suspended in a single component vehicle. The single component vehicle is a single amphiphilic material, such as a polyethoxylated castor oil or derivative thereof, a polyoxyethylene alkyl ether, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene stearate, a block copolymer of polyethylene oxide-polypropylene oxide-polyethylene oxide, a block copolymer of polypropylene oxide-polyethylene oxide-polypropylene oxide, a tetra-functional block copolymer of polyethylene oxide-polypropylene oxide, or a tetra-functional block copolymer of polypropylene oxide-polyethylene oxide. A dosage kit that includes the injectable, nonaqueous suspension and a method of administering the injectable, nonaqueous suspension are also disclosed.Type: GrantFiled: October 26, 2011Date of Patent: August 12, 2014Assignee: Durect CorporationInventors: Paul R. Houston, Guohua Chen, Andrew Sheung-King Luk
-
Patent number: 8802133Abstract: Disclosed is 1) a method for greatly increasing the solubility of useful actives in siloxane matrix-forming preparations, and 2) the associated preparations, themselves. Volatilizing coagents are utilized to give novel gels containing heretofore siloxane-insoluble additives.Type: GrantFiled: July 13, 2012Date of Patent: August 12, 2014Assignee: Advanced Bio-Technologies, Inc.Inventor: Paul Guilbaud
-
Patent number: 8802644Abstract: The invention features a cationic lipid of formula I, an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.Type: GrantFiled: January 25, 2012Date of Patent: August 12, 2014Assignee: Tekmira Pharmaceuticals CorporationInventors: Jianxin Chen, Steven Ansell, Akin Akinc, Joseph Robert Dorkin, Xiaojun Qin, William Cantley, Muthiah Manoharan, Kallanthottathil G. Rajeev, Jayaprakash K. Narayanannair, Muthusamy Jayaraman
-
Patent number: 8795634Abstract: Absorption of a therapeutic agent across a mucosal membrane or the skin can be enhanced using an absorption enhancer comprising a hydroxy fatty acid ester of polyethylene glycol.Type: GrantFiled: September 14, 2009Date of Patent: August 5, 2014Assignee: Critical Pharmaceuticals LimitedInventors: Lisbeth Illum, Faron Michael Jordan, Andrew Lester Lewis
-
Publication number: 20140212466Abstract: The invention provides a method for the preparation of a carrier liquid which comprises the steps of: (I) preparing a single phase solution comprising: (a) a solvent or a mixture of miscible solvents, (b) a liquid carrier material, which is soluble in solvent (a), and (c) a dopant material which is also soluble in solvent (a); (II) cooling (preferably freezing) the single phase solution produced in step (I) to a temperature at which at least both the solvent (a) and carrier material (b) become solid; and (III) removing solid solvent (a) from the cooled (frozen) single phase solution in vapour form, such that the remaining cooled (frozen) carrier material (b) and dopant material (c) are returned to ambient temperature thus providing a product of liquid carrier material (b) having dopant material (c) dispersed therein.Type: ApplicationFiled: August 20, 2012Publication date: July 31, 2014Applicant: IOTA NANOSOLUTIONS LIMITEDInventors: Alison Jayne Foster, James Long, Steven Paul Rannard, Dong Wang
-
Publication number: 20140213637Abstract: New cationic lipids are provided that are useful for delivering macromolecules, such as nucleic acids, into eukaryotic cells. The lipids can be used alone, in combination with other lipids and/or in combination with other transfection enhancing reagents to prepare transfection complexes.Type: ApplicationFiled: October 16, 2013Publication date: July 31, 2014Applicant: Molecular Transfer Inc.Inventors: Joel Jessee, Gulilat Gebeyehu
-
Publication number: 20140206542Abstract: An agricultural oil-based suspension formulation comprising an active ingredient suspended in finely divided form in an oil; and at least one surfactant selected from a polyalkylene glycol-fatty acid condensate or a polyalkylene glycolether fatty acid condensate formed from a reaction between a compound having Structure (1) and a compound having Structure (2): wherein R1=H or a C1-C30 alkyl radical; A and B are ethylene or propylene groups in succession or random; n=0 or >1; and m=0 or >1, and wherein n+m>34; R2=C8-C30 alkyl or alkylene radical (branched or linear); and x=>1.Type: ApplicationFiled: June 8, 2012Publication date: July 24, 2014Applicant: Huntsman Corporation Australia Pty LimitedInventors: Keith Moody, Dilek Saylik, Rowan Brown
-
Publication number: 20140206616Abstract: Disclosed is a sustained release lipid pre-concentrate, comprising: a) a sorbitan unsaturated fatty acid ester having a polar head with at least two or more —OH (hydroxyl) groups; b) a phospholipid; and c) a liquid crystal hardener, free of an ionizable group, having a hydrophobic moiety of 15 to 40 carbon atoms with a triacyl group or a carbon ring structure. The lipid pre-concentrate exists as a liquid phase in the absence of aqueous fluid and forms into a liquid crystal in the presence of aqueous fluid. Also, a pharmaceutical composition further comprising a pharmacologically active ingredient plus the pre-concentrate is provided.Type: ApplicationFiled: August 28, 2012Publication date: July 24, 2014Applicant: Chong Kun Dang Pharmaceutical Corp.Inventors: Jin Young Ko, Ji Yeon Kim, So Hyun Park, Sung Won An, Min Hyo Ki
-
Publication number: 20140200257Abstract: The invention provides poly(ethylene glycol)-lipid conjugates for use in drug delivery.Type: ApplicationFiled: January 11, 2012Publication date: July 17, 2014Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Kallanthottathil G Rajeev, Muthiah Manoharan, Muthusamy Jayaraman, Martin Maier, Jayaprakash K. Nair, David Butler
-
Patent number: 8779010Abstract: The present invention provides a water-in-oil emulsion cosmetic that is excellent in the resilient and supple (in other words, firm and tensional) feels and also excellent in the moisturizing effect and feeling in use. The water-in-oil emulsion cosmetic of the present invention is characterized by comprising the following (A) to (D): (A) 0.5 to 10 mass % of bis-diglyceryl polyacyladipate-2 (B) an oil containing (b1) (b1) a volatile oil of low compatibility with (A) (C) an emulsifying agent and (D) 60 to 90 mass % of an aqueous component, wherein the percentage of component (b1) is 40 to 85% with respect to component (A) and component (B).Type: GrantFiled: March 29, 2012Date of Patent: July 15, 2014Assignee: Shiseido Company, Ltd.Inventors: Masaki Kitajima, Ayako Ibe, Kei Watanabe, Takayuki Omura
-
Publication number: 20140194536Abstract: The present invention relates to a liquid crystal compound that can be used as a base for injection formulations. The present invention provides an amphipathic compound having the following general formula (I): wherein X and Y each denotes a hydrogen atom or together denote an oxygen atom, n denotes an integer from 0 to 2, m denotes the integer 1 or 2, and R denotes a hydrophilic group generated by removal of one hydroxyl group from any one selected from the group consisting of glycerol, erythritol, pentaerythritol, diglycerol, triglycerol, xylose, sorbitol, ascorbic acid, glucose, galactose, mannose, dipentaerythritol, maltose, mannitol, and xylitol; as well as a base for injection formulations and depot formulation comprising the same.Type: ApplicationFiled: February 28, 2014Publication date: July 10, 2014Applicant: Chemgenesis IncorporatedInventors: Yutaka Ikeda, Jun Yamashita, Ichiro Hijikuro, Satoshi Imuta, Yasuhiro Hiroki, Takashi Takahashi